Articles

Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups

Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan
Division of Hematology, National Defense Medical College, Tokorozawa, Japan
Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan
Department of Hematology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan
Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan
Department of Hematology, Gifu University Hospital, Tokyo, Japan
Department of Hematology, Toranomon Hospital, Tokyo, Japan
Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan
Hematology Division, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Fukuoka, Japan
Department of Hematology, Japanese Red Cross Nagoya First Hospital, Fukuoka, Japan
Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan
Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan;Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan
Department of Hematology and Oncology, Children’s Medical Center, Japanese Red Cross Nagoya First Hospital, Japan
Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan
Department of Hematology/Oncology, Osaka Medical Center and Research Institute for Maternal and Child Health, Japan
Department of Hematology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Vol. 101 No. 12 (2016): December, 2016 https://doi.org/10.3324/haematol.2016.149427